title: Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies.
abstract: Hypoxia is a common feature in tumors associated with an increased resistance of tumor cells to therapies. In addition to O(2) diffusion-limited hypoxia, another form of tumor hypoxia characterized by fluctuating changes in pO(2) within the disorganized tumor vascular network is described. Here, we postulated that this form of intermittent hypoxia promotes endothelial cell survival, thereby extending the concept of hypoxia-driven resistance to the tumor vasculature. We found that endothelial cell exposure to cycles of hypoxia reoxygenation not only rendered them resistant to proapoptotic stresses, including serum deprivation and radiotherapy, but also increased their capacity to migrate and organize in tubes. By contrast, prolonged hypoxia failed to exert protective effects and even seemed deleterious when combined with radiotherapy. The use of hypoxia-inducible factor-1alpha (HIF-1alpha)-targeting small interfering RNA led us to document that the accumulation of HIF-1alpha during intermittent hypoxia accounted for the higher resistance of endothelial cells. We also used an in vivo approach to enforce intermittent hypoxia in tumor-bearing mice and found that it was associated with less radiation-induced apoptosis within both the vascular and the tumor cell compartments (versus normoxia or prolonged hypoxia). Radioresistance was further ascertained by an increased rate of tumor regrowth in irradiated mice preexposed to intermittent hypoxia and confirmed in vitro using distinctly radiosensitive tumor cell lines. In conclusion, we have documented that intermittent hypoxia may condition endothelial cells and tumor cells in such a way that they are more resistant to apoptosis and more prone to participate in tumor progression. Our observations also underscore the potential of drugs targeting HIF-1alpha to resensitize the tumor vasculature to anticancer treatments.
authors.affiliation: Unit of Pharmacology and Therapeutics (FATH 5349), Université Catholique de Louvain, B-1200 Brussels, Belgium.
authors.forename: Philippe
authors.initials: P
authors.lastname: Martinive
authors.forename: Florence
authors.initials: F
authors.lastname: Defresne
authors.forename: Caroline
authors.initials: C
authors.lastname: Bouzin
authors.forename: Julie
authors.initials: J
authors.lastname: Saliez
authors.forename: Florence
authors.initials: F
authors.lastname: Lair
authors.forename: Vincent
authors.initials: V
authors.lastname: Grégoire
authors.forename: Carine
authors.initials: C
authors.lastname: Michiels
authors.forename: Chantal
authors.initials: C
authors.lastname: Dessy
authors.forename: Olivier
authors.initials: O
authors.lastname: Feron
mesh_terms: D000818:Animals; D002455:Cell Division; D015687:Cell Hypoxia / Q000502:physiology*; D045744:Cell Line, Tumor; D006801:Humans; D019194:Ischemic Preconditioning / Q000379:methods*; D008113:Liver Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009389:Neovascularization, Pathologic / Q000503:physiopathology